COMPARE · Reviewed July 30, 2026
AZN vs BHC
Verdict: Side-by-side breakdown using the Bull Rankings model. AZN scored 80.0, BHC scored 70.1 — AZN leads.
Compare another set
AZN
AstraZeneca PLC
80
$171.34
fundamentals as of
Score gap
9.9
AZN leads
BHC
Bausch Health Companies Inc.
70.1
$6.03 · $2.3B
fundamentals as of
Fundamentals, head-to-head
AZN
BHC
$6.0bB+
FCF
$1.4bC+
+8.6%B
Rev
+10.1%B
0.64C+
D/E
—
25.7xB
P/E
—
1.34B
PEG
0.01A
—
P/S
0.2xA
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
AZN
BHC
—
Price vs fair valuelower is cheaper
87% below
—
Growth the price implies10-yr FCF · lower = less priced in
decline
—
1-yr DCF upside
+767%
—
5-yr DCF upside
+684%
—
10-yr DCF upside
+583%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
AZN
No notable signals flagged.
BHC
Why this score
- Short track record
The companies
AZNAstraZeneca PLC
Why now
Drug Manufacturers - General · market cap n/a. 19% off the 52-week high of $212.71. 10 sell-side analysts rate this a Buy with a mean 1-yr target of $213.59 (implying +25% upside).
Moat
Net margin 17% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 22% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
BHCBausch Health Companies Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $2.3b. Down 31% from 52-week high of $8.69 — deep drawdown territory. Revenue growing +10%, comfortably above the S&P median. PEG 0.01 — paying under fair value for the growth rate. 5 sell-side analysts rate this a Hold with a mean 1-yr target of $7.30 (implying +21% upside).
Moat
ROE 62% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Currently unprofitable (margin -10.1%) — path to GAAP profitability is the core thesis risk. Down 31% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.